JOHN KIRKWOOD to Humans
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Humans.
Connection Strength
2.770
-
Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas. J Immunother Cancer. 2024 Nov 12; 12(11).
Score: 0.026
-
Assessing clonal changes in T?cells over time following immunotherapy is a breeze with Cyclone. Cancer Cell. 2024 Sep 09; 42(9):1491-1493.
Score: 0.026
-
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C?melanoma is removed by surgery. Future Oncol. 2024 May; 20(15):959-968.
Score: 0.025
-
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study. Immunotherapy. 2024 01; 16(1):29-42.
Score: 0.024
-
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023 Nov; 29(11):2835-2843.
Score: 0.024
-
Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol. 2023 05 01; 159(5):545-553.
Score: 0.024
-
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. Eur J Cancer. 2022 11; 176:207-217.
Score: 0.023
-
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197.
Score: 0.023
-
Multiple primary melanoma in association with other personal and familial cancers. Cancer Med. 2023 02; 12(3):2474-2483.
Score: 0.022
-
Poorer survival outcomes in patients with multiple versus single primary melanoma. Cancer. 2022 06 01; 128(11):2098-2106.
Score: 0.022
-
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022 01; 10(1).
Score: 0.021
-
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021 11; 9(11).
Score: 0.021
-
Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res. 2022 01; 35(1):66-77.
Score: 0.021
-
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5).
Score: 0.020
-
Cancer vaccine induces potent T cell responses - but is it enough? Nat Rev Clin Oncol. 2020 12; 17(12):721-722.
Score: 0.020
-
Indoor tanning exposure in association with multiple primary melanoma. Cancer. 2021 02 15; 127(4):560-568.
Score: 0.020
-
State of Melanoma: An Historic Overview of a Field in Transition. Hematol Oncol Clin North Am. 2021 02; 35(1):1-27.
Score: 0.020
-
Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
Score: 0.019
-
Developing agents for the therapeutic prevention of melanoma: can the assessment of cutaneous precursor lesions help? Future Oncol. 2020 Mar; 16(9):413-415.
Score: 0.019
-
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020 02 20; 38(6):567-575.
Score: 0.019
-
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade. JAMA Oncol. 2019 07 01; 5(7):942-943.
Score: 0.018
-
An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. Cancer. 2019 09 01; 125(17):3013-3024.
Score: 0.018
-
Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
Score: 0.018
-
E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-a2b in Advanced Melanoma. Clin Cancer Res. 2019 01 15; 25(2):524-532.
Score: 0.017
-
Neoadjuvant ipilimumab (3?mg/kg or 10?mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018 10 23; 6(1):112.
Score: 0.017
-
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341.
Score: 0.017
-
Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila). 2018 07; 11(7):429-438.
Score: 0.017
-
Adjuvant Therapy in Resected Melanoma. N Engl J Med. 2018 02 15; 378(7):679-680.
Score: 0.016
-
A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma. Melanoma Res. 2017 10; 27(5):429-438.
Score: 0.016
-
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 11 09; 377(19):1813-1823.
Score: 0.016
-
Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017 Nov 15; 23(22):6888-6892.
Score: 0.016
-
A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol. 2017 Aug 01; 3(8):1112-1115.
Score: 0.016
-
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma. Melanoma Res. 2017 08; 27(4):342-350.
Score: 0.016
-
Collaborative Care in Melanoma: The Essential Role of the Nurse?. Clin J Oncol Nurs. 2017 08 01; 21(4 Suppl):4-6.
Score: 0.016
-
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer. 2017 Jul 15; 123(14):2688-2697.
Score: 0.015
-
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-a-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017 Mar 10; 35(8):885-892.
Score: 0.015
-
Downstream consequences of melanoma screening in a community practice setting: First results. Cancer. 2016 Oct 15; 122(20):3152-3156.
Score: 0.015
-
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):632-46.
Score: 0.015
-
BRAF Inhibitors and IFNa: Plus, Minus, or Indeterminate? J Natl Cancer Inst. 2016 Jul; 108(7).
Score: 0.014
-
Adjuvant Therapy of Melanoma. Cancer Treat Res. 2016; 167:181-208.
Score: 0.014
-
CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux. Clin Cancer Res. 2015 Dec 15; 21(24):5412-4.
Score: 0.014
-
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med. 2015 Sep 30; 13:319.
Score: 0.014
-
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol. 2015 Dec 01; 33(34):4066-76.
Score: 0.014
-
Unfolding the mutational landscape of human melanoma. J Invest Dermatol. 2015 Mar; 135(3):659-662.
Score: 0.013
-
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014 Nov 05; 312(17):1744-53.
Score: 0.013
-
State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am. 2014 Jun; 28(3):415-35.
Score: 0.013
-
Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res. 2014 Apr; 24(2):150-7.
Score: 0.013
-
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705.
Score: 0.012
-
A four-marker signature of TNF-RII, TGF-a, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014 Jan 23; 12:19.
Score: 0.012
-
Advances in adjuvant therapy: potential for prognostic and predictive biomarkers. Methods Mol Biol. 2014; 1102:45-69.
Score: 0.012
-
ECOG phase II trial of graded-dose peginterferon a-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res. 2013 Dec 01; 19(23):6597-604.
Score: 0.012
-
Pediatric melanoma: analysis of an international registry. Cancer. 2013 Nov 15; 119(22):4012-9.
Score: 0.012
-
A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res. 2013 Aug 01; 19(15):4228-38.
Score: 0.012
-
Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol. 2013 May-Jun; 31(3):237-50.
Score: 0.012
-
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013 Jan 20; 31(3):373-9.
Score: 0.011
-
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol. 2013 Apr; 24(4):1112-9.
Score: 0.011
-
Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-a or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother. 2012 Nov-Dec; 35(9):702-10.
Score: 0.011
-
IFN-a in the treatment of melanoma. J Immunol. 2012 Oct 15; 189(8):3789-93.
Score: 0.011
-
How much of a good thing? What duration for interferon alfa-2b adjuvant therapy? J Clin Oncol. 2012 Nov 01; 30(31):3773-6.
Score: 0.011
-
Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis. 2012 Oct; 29(7):775-96.
Score: 0.011
-
Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect. Nat Rev Clin Oncol. 2012 Sep; 9(9):496-7.
Score: 0.011
-
New therapies in the treatment of melanoma. Expert Opin Investig Drugs. 2012 Nov; 21(11):1643-59.
Score: 0.011
-
Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012 Sep-Oct; 62(5):309-35.
Score: 0.011
-
Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother. 2012 May; 35(4):359-66.
Score: 0.011
-
Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. Cancer Treat Rev. 2013 Feb; 39(1):27-43.
Score: 0.011
-
Adjuvant therapy for melanoma. Cancer J. 2012 Mar-Apr; 18(2):192-202.
Score: 0.011
-
Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients. J Immunol Methods. 2012 Feb 28; 376(1-2):108-12.
Score: 0.011
-
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012 Jan 20; 30(3):322-8.
Score: 0.011
-
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):336-41.
Score: 0.011
-
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):555-67.
Score: 0.011
-
Multiplex serum biomarker assessments: technical and biostatistical issues. J Transl Med. 2011 Oct 11; 9:173.
Score: 0.011
-
Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res. 2011 Dec 01; 17(23):7451-61.
Score: 0.011
-
Neoadjuvant therapy for high-risk bulky regional melanoma. J Surg Oncol. 2011 Sep; 104(4):386-90.
Score: 0.010
-
Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011 Oct 15; 17(20):6574-81.
Score: 0.010
-
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer. 2011 Sep 06; 105(6):773-7.
Score: 0.010
-
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. 2011 Oct 15; 117(20):4732-9.
Score: 0.010
-
Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol. 2011 Jul; 33(4):385-91.
Score: 0.010
-
CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma. Oncology (Williston Park). 2010 Dec; 24(14):1302, 1304.
Score: 0.010
-
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med. 2010 Nov 03; 8:108.
Score: 0.010
-
Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. J Immunother. 2010 Jul-Aug; 33(6):630-8.
Score: 0.010
-
Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010 Apr; 133(4):646-53.
Score: 0.009
-
Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. J Immunother. 2010 Apr; 33(3):316-25.
Score: 0.009
-
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010 Feb 01; 16(3):1042-8.
Score: 0.009
-
Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci. 2009 Dec; 1182:47-57.
Score: 0.009
-
Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol. 2009 Oct; 36(5):419-31.
Score: 0.009
-
Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol. 2009 Jun 01; 27(16):2583-5.
Score: 0.009
-
Highlights from the perspectives in melanoma XII conference. Pigment Cell Melanoma Res. 2009 Apr; 22(2):156-65.
Score: 0.009
-
Predictors of response to interferon therapy. Curr Opin Oncol. 2009 Mar; 21(2):138-43.
Score: 0.009
-
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009 Feb 15; 115(4):859-68.
Score: 0.009
-
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009 Feb 15; 15(4):1443-51.
Score: 0.009
-
Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res. 2008 Dec 15; 14(24):8314-20.
Score: 0.009
-
Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009 Jan 01; 27(1):38-44.
Score: 0.009
-
Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med. 2008 Oct 27; 6:62.
Score: 0.009
-
Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther. 2008 Oct; 8(10):1583-93.
Score: 0.009
-
Next generation of immunotherapy for melanoma. J Clin Oncol. 2008 Jul 10; 26(20):3445-55.
Score: 0.008
-
Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma. Cancer Immunol Immunother. 2008 Sep; 57(9):1315-21.
Score: 0.008
-
STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. J Invest Dermatol. 2008 Aug; 128(8):1997-2002.
Score: 0.008
-
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb 01; 26(4):527-34.
Score: 0.008
-
Management of metastatic melanoma. Semin Oncol. 2007 Dec; 34(6):532-45.
Score: 0.008
-
Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol. 2008 Jan; 5(1):2-3.
Score: 0.008
-
Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Curr Opin Mol Ther. 2007 Oct; 9(5):505-14.
Score: 0.008
-
Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma. Cytokine Growth Factor Rev. 2007 Oct-Dec; 18(5-6):451-8.
Score: 0.008
-
Integrins and cancer. Oncology (Williston Park). 2007 Aug; 21(9 Suppl 3):13-20.
Score: 0.008
-
Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res. 2007 Jun; 17(3):193-200.
Score: 0.008
-
Oblimersen in the treatment of metastatic melanoma. Future Oncol. 2007 Jun; 3(3):263-71.
Score: 0.008
-
Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res. 2007 Mar 01; 13(5):1523-31.
Score: 0.008
-
Molecularly targeted therapy for melanoma: current reality and future options. Cancer. 2006 Nov 15; 107(10):2317-27.
Score: 0.008
-
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006 Jul 01; 24(19):3164-71.
Score: 0.007
-
Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b". Oncologist. 2006 May; 11(5):538-9; author reply 539-40.
Score: 0.007
-
Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2331s-2336s.
Score: 0.007
-
Radiosurgery for the treatment of spinal melanoma metastases. Stereotact Funct Neurosurg. 2005; 83(5-6):213-21.
Score: 0.007
-
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16; 354(7):709-18.
Score: 0.007
-
Building upon the standard of care in adjuvant therapy of high-risk melanoma. J Clin Oncol. 2005 Dec 01; 23(34):8559-63.
Score: 0.007
-
Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma? Nat Clin Pract Oncol. 2005 May; 2(5):240-1.
Score: 0.007
-
Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma. J Immunother Cancer. 2025 Feb 12; 13(2).
Score: 0.007
-
Melanoma. Cancer Chemother Biol Response Modif. 2005; 22:563-90.
Score: 0.007
-
Interferons in the treatment of solid tumors. Cancer Treat Res. 2005; 126:207-41.
Score: 0.007
-
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024 Nov 11; 42(11):1898-1918.e12.
Score: 0.007
-
Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. J Clin Oncol. 2025 Mar 20; 43(9):1157-1167.
Score: 0.006
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
Score: 0.006
-
Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients. Melanoma Res. 2024 Dec 01; 34(6):544-548.
Score: 0.006
-
LAG-3 and PD-1 synergize on CD8+ T?cells to drive T cell exhaustion and hinder autocrine IFN-?-dependent anti-tumor immunity. Cell. 2024 Aug 08; 187(16):4355-4372.e22.
Score: 0.006
-
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024 Aug 08; 187(16):4373-4388.e15.
Score: 0.006
-
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004 Aug; 40(12):1825-36.
Score: 0.006
-
Melanoma in the older person. Oncology (Williston Park). 2004 Aug; 18(9):1187-96; discussion 1196-7.
Score: 0.006
-
Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy. Oncologist. 2024 Jul 05; 29(7):619-628.
Score: 0.006
-
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 Nov 07; 391(18):1709-1720.
Score: 0.006
-
Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res. 2004 Jun; 14(3):217-22.
Score: 0.006
-
GZ17-6.02 kills PDX isolates of uveal melanoma. Oncotarget. 2024 May 17; 15:328-344.
Score: 0.006
-
Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis. JAMA Oncol. 2024 May 01; 10(5):612-620.
Score: 0.006
-
Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004 Apr 15; 100(8):1692-8.
Score: 0.006
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. J Immunother Cancer. 2024 Mar 13; 12(3).
Score: 0.006
-
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 May 10; 42(14):1619-1624.
Score: 0.006
-
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004 Mar 01; 10(5):1670-7.
Score: 0.006
-
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Res Commun. 2023 12 19; 3(12):2572-2584.
Score: 0.006
-
Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts. Cancer Med. 2023 12; 12(24):22103-22108.
Score: 0.006
-
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2023 Dec 14; 389(24):2256-2266.
Score: 0.006
-
Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. J Immunother Cancer. 2023 10; 11(10).
Score: 0.006
-
Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 10 20; 41(30):4794-4820.
Score: 0.006
-
Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes. Front Immunol. 2023; 14:1171978.
Score: 0.006
-
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. J Immunother Cancer. 2023 06; 11(6).
Score: 0.006
-
Medical management of melanoma. Surg Clin North Am. 2003 Apr; 83(2):283-322, viii.
Score: 0.006
-
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 03 02; 388(9):813-823.
Score: 0.006
-
Adjuvant therapy of melanoma. Semin Cutan Med Surg. 2003 Mar; 22(1):55-67.
Score: 0.006
-
Melanoma vaccines: early progress and future promises. Semin Cutan Med Surg. 2003 Mar; 22(1):68-75.
Score: 0.006
-
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA Oncol. 2023 02 01; 9(2):251-260.
Score: 0.006
-
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clin Cancer Res. 2023 02 01; 29(3):521-531.
Score: 0.006
-
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.
Score: 0.006
-
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer. 2003 Jan 01; 97(1):121-7.
Score: 0.006
-
Sentinel lymph node biopsy and adjuvant therapy for melanoma: evidence revisited. Arch Dermatol. 2003 Jan; 139(1):99; author reply 99-100.
Score: 0.006
-
Adjuvant high-dose interferon-alpha therapy for high-risk melanoma. Forum (Genova). 2003; 13(2):127-40; quiz 187-8.
Score: 0.006
-
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022 12 01; 28(23):5030-5039.
Score: 0.006
-
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022 12; 10(12).
Score: 0.006
-
TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma. Science. 2022 Nov 11; 378(6620):664-668.
Score: 0.006
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022 11; 23(11):1378-1388.
Score: 0.006
-
Use and abuse of statistics in evidence-based medicine. J Clin Oncol. 2002 Oct 01; 20(19):4122-3; author reply 4123-4.
Score: 0.006
-
Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002 Sep 01; 20(17):3703-18.
Score: 0.006
-
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 2002 Sep 01; 95(5):1101-12.
Score: 0.006
-
Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Williston Park). 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197.
Score: 0.006
-
Patient-reported tolerability of adjuvant ipilimumab (3 or 10?mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. Qual Life Res. 2023 Jan; 32(1):183-196.
Score: 0.006
-
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 01 20; 41(3):528-540.
Score: 0.006
-
Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res. 2002 Aug; 8(8):2480-7.
Score: 0.006
-
Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors. J Transl Med. 2022 07 25; 20(1):331.
Score: 0.006
-
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol. 2022 11 10; 40(32):3741-3749.
Score: 0.006
-
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253.
Score: 0.006
-
Cancer immunotherapy: the interferon-alpha experience. Semin Oncol. 2002 Jun; 29(3 Suppl 7):18-26.
Score: 0.006
-
Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. Ann Surg Oncol. 2022 Sep; 29(9):5948-5956.
Score: 0.006
-
A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma. J Am Acad Dermatol. 2022 10; 87(4):906-908.
Score: 0.005
-
Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System. JAMA Dermatol. 2022 05 01; 158(5):504-512.
Score: 0.005
-
Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol. 2002 Apr 15; 20(8):2053-7.
Score: 0.005
-
Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002 Apr; 13(2):119-34.
Score: 0.005
-
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 04 30; 399(10336):1718-1729.
Score: 0.005
-
Interferon alfa-2a for melanoma metastases. Lancet. 2002 Mar 16; 359(9310):978-9.
Score: 0.005
-
Adjuvant Pembrolizumab versus IFNa2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022 03 01; 12(3):644-653.
Score: 0.005
-
Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunol Res. 2022 03 01; 10(3):303-313.
Score: 0.005
-
NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002 Jan 01; 62(1):213-8.
Score: 0.005
-
An update on adjuvant interferon for melanoma. Cancer Control. 2002 Jan-Feb; 9(1):16-21.
Score: 0.005
-
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
Score: 0.005
-
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 09 23; 385(13):1196-1206.
Score: 0.005
-
Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI. J Clin Oncol. 2001 Sep 01; 19(17):3794.
Score: 0.005
-
Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol. 2001 Sep; 137(9):1217-24.
Score: 0.005
-
Targeted therapy for malignant melanoma. Curr Oncol Rep. 2001 Jul; 3(4):344-52.
Score: 0.005
-
Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases. Melanoma Res. 2021 06 01; 31(3):264-267.
Score: 0.005
-
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021 08 20; 39(24):2656-2666.
Score: 0.005
-
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001 May 01; 19(9):2370-80.
Score: 0.005
-
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology. 2021 03 26; 10(1):1898105.
Score: 0.005
-
Neoadjuvant Pembrolizumab and High-Dose IFNa-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res. 2021 08 01; 27(15):4195-4204.
Score: 0.005
-
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001 Mar 01; 19(5):1430-6.
Score: 0.005
-
Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression. J Extracell Vesicles. 2021 02; 10(4):e12063.
Score: 0.005
-
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 02 05; 371(6529):595-602.
Score: 0.005
-
The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 05 15; 27(10):2678-2697.
Score: 0.005
-
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challenges. J Immunother Cancer. 2020 12; 8(2).
Score: 0.005
-
Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines. SLAS Discov. 2021 06; 26(5):712-729.
Score: 0.005
-
Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000 Nov 15; 18(22):3782-93.
Score: 0.005
-
Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res. 2020 12; 8(12):1554-1567.
Score: 0.005
-
Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020 11; 9(22):8650-8661.
Score: 0.005
-
Biologic therapy. Clin Plast Surg. 2000 Oct; 27(4):643-65.
Score: 0.005
-
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges. J Immunother Cancer. 2020 10; 8(2).
Score: 0.005
-
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 09 17; 383(12):1139-1148.
Score: 0.005
-
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 2000 Sep 01; 60(17):4946-52.
Score: 0.005
-
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 09 01; 156(9):1004-1011.
Score: 0.005
-
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020 07 17; 5(49).
Score: 0.005
-
Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. J Exp Med. 2020 07 06; 217(7).
Score: 0.005
-
Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 2000 Jul-Sep; 10(3):230-9.
Score: 0.005
-
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020 10 15; 26(20):5520-5533.
Score: 0.005
-
Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer. 2000 Jun 15; 88(12):2693-702.
Score: 0.005
-
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun; 18(12):2444-58.
Score: 0.005
-
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020 06; 8(1).
Score: 0.005
-
Activation of p38a stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs. Nat Cancer. 2020 06; 1(6):603-619.
Score: 0.005
-
Adjuvant interferon in the treatment of melanoma. Br J Cancer. 2000 May; 82(10):1755-6.
Score: 0.005
-
Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma. Oncologist. 2020 08; 25(8):e1209-e1220.
Score: 0.005
-
Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol. 2000 Apr; 18(8):1603-5.
Score: 0.005
-
Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 11 20; 38(33):3947-3970.
Score: 0.005
-
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 03; 21(3):358-372.
Score: 0.005
-
Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Sci Rep. 2020 01 09; 10(1):92.
Score: 0.005
-
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000; 5(2):144-51.
Score: 0.005
-
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
Score: 0.005
-
A Th1/IFN? Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 04 01; 26(7):1725-1735.
Score: 0.005
-
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2019 12 10; 37(35):3350-3358.
Score: 0.005
-
Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer. 2019 09 04; 7(1):239.
Score: 0.005
-
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999 Sep; 17(9):2745-51.
Score: 0.005
-
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389.
Score: 0.005
-
Thick melanoma is associated with low melanoma knowledge and low perceived health competence, but not delays in care. J Am Acad Dermatol. 2020 08; 83(2):587-590.
Score: 0.004
-
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer. 1999 May 01; 85(9):1979-84.
Score: 0.004
-
Reply to E. Hindi? and K.R. Hess. J Clin Oncol. 2019 05 20; 37(15):1356-1358.
Score: 0.004
-
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 05; 20(5):701-710.
Score: 0.004
-
Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019 03 07; 4(5).
Score: 0.004
-
PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy. Sci Rep. 2019 03 01; 9(1):3309.
Score: 0.004
-
CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-a. Front Immunol. 2019; 10:14.
Score: 0.004
-
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell. 2019 01 14; 35(1):33-45.e6.
Score: 0.004
-
Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med. 1999 Jan; 5(1):11-20.
Score: 0.004
-
Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gaq and Ga11 and kill uveal melanoma cells. Cancer Biol Ther. 2019; 20(5):700-710.
Score: 0.004
-
Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy. Clin Exp Immunol. 1998 Dec; 114(3):347-54.
Score: 0.004
-
Psychosocial impact of skin biopsies in the setting of melanoma screening: a cross-sectional survey. Br J Dermatol. 2019 03; 180(3):664-665.
Score: 0.004
-
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018 12 10; 36(35):3441-3449.
Score: 0.004
-
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. J Clin Oncol. 2019 01 01; 37(1):72-80.
Score: 0.004
-
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108.
Score: 0.004
-
Adjuvant interferon treatment for melanoma. Hematol Oncol Clin North Am. 1998 Aug; 12(4):823-33.
Score: 0.004
-
Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Eur J Cancer. 1998 Jul; 34 Suppl 3:S12-7.
Score: 0.004
-
Adjuvant IFN alpha2 therapy of melanoma. Lancet. 1998 Jun 27; 351(9120):1901-3.
Score: 0.004
-
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 07; 19(7):916-929.
Score: 0.004
-
Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res. 2018 06; 28(3):211-221.
Score: 0.004
-
Adjuvant therapy of melanoma. Semin Surg Oncol. 1998 Jun; 14(4):302-10.
Score: 0.004
-
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44.
Score: 0.004
-
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018 05 14; 6(1):35.
Score: 0.004
-
Anti-PD-1 antibody treatment for melanoma. Lancet Oncol. 2018 05; 19(5):e219.
Score: 0.004
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
Score: 0.004
-
Management strategies of academic pigmented lesion clinic directors in the United States. J Am Acad Dermatol. 2018 Aug; 79(2):367-369.
Score: 0.004
-
Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. J Natl Cancer Inst. 2018 01 01; 110(1).
Score: 0.004
-
Survival benefit in melanoma. J Clin Oncol. 1998 Jan; 16(1):388-9.
Score: 0.004
-
Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol. 2018 Feb; 25(2):356-377.
Score: 0.004
-
Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 02 01; 36(4):399-413.
Score: 0.004
-
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biol Ther. 2018 02 01; 19(2):132-137.
Score: 0.004
-
Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol. 2018 04; 78(4):701-709.e1.
Score: 0.004
-
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. J Clin Oncol. 2018 02 01; 36(4):391-398.
Score: 0.004
-
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov; 67(6):472-492.
Score: 0.004
-
High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017 Nov; 6(11):2576-2585.
Score: 0.004
-
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight. 2017 09 21; 2(18).
Score: 0.004
-
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017 09 19; 5(1):74.
Score: 0.004
-
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017 Dec 01; 35(34):3815-3822.
Score: 0.004
-
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10.
Score: 0.004
-
Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients. J Immunother. 1997 Sep; 20(5):387-98.
Score: 0.004
-
Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. J Immunother Cancer. 2017 08 15; 5(1):67.
Score: 0.004
-
Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity. Eur J Cancer. 1997 Aug; 33(9):1345-6.
Score: 0.004
-
Adjuvant interferon-a for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017 09; 82:171-183.
Score: 0.004
-
Interferon-? Drives Treg Fragility to Promote Anti-tumor Immunity. Cell. 2017 Jun 01; 169(6):1130-1141.e11.
Score: 0.004
-
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res. 2017 Sep 01; 23(17):5034-5043.
Score: 0.004
-
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017; 5:44.
Score: 0.004
-
Interferon adjuvant therapy of melanoma. Cancer. 1997 May 01; 79(9):1843-6.
Score: 0.004
-
Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. Cancer Immunol Immunother. 1997 May; 44(3):137-49.
Score: 0.004
-
Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma. Sci Rep. 2017 04 05; 7:45704.
Score: 0.004
-
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017 Mar 07; 8(10):16367-16386.
Score: 0.004
-
Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group. J Immunother. 1997 Mar; 20(2):146-57.
Score: 0.004
-
The adjuvant treatment of malignant melanoma. J Fla Med Assoc. 1997 Mar; 84(3):147-52.
Score: 0.004
-
Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol. 1997 Feb; 24(1 Suppl 4):S16-23.
Score: 0.004
-
Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery. J Neurosurg. 2018 01; 128(1):14-22.
Score: 0.004
-
Adjuvant application of interferons. Semin Oncol. 1996 Dec; 23(6):737-43.
Score: 0.004
-
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016 12; 65(12):1533-1544.
Score: 0.004
-
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin Cancer Res. 1996 Jul; 2(7):1129-34.
Score: 0.004
-
Association of TERT promoter mutations with telomerase expression in melanoma. Pigment Cell Melanoma Res. 2016 May; 29(3):391-3.
Score: 0.004
-
The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 07; 29(4):404-16.
Score: 0.004
-
Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Rep. 2016 Apr 05; 15(1):171-180.
Score: 0.004
-
Malignant melanoma metastatic to the tonsil. Laryngoscope. 1996 Mar; 106(3 Pt 1):313-6.
Score: 0.004
-
Interferons in melanoma. Curr Opin Oncol. 1996 Mar; 8(2):167-74.
Score: 0.004
-
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan; 14(1):7-17.
Score: 0.004
-
Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol. 2016 Jan; 136(1):339-342.
Score: 0.004
-
Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am. 1995 Nov-Dec; 1(4):274-80.
Score: 0.003
-
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res. 2016 Jan 15; 22(2):374-82.
Score: 0.003
-
Intermediate-grade meningeal melanocytoma associated with nevus of Ota: a case report and review of the literature. Melanoma Res. 2015 Aug; 25(4):273-8.
Score: 0.003
-
Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Ann Surg Oncol. 1995 Jul; 2(4):365-71.
Score: 0.003
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
Score: 0.003
-
Transcriptional repression of IFN?1 by ATF2 confers melanoma resistance to therapy. Oncogene. 2015 Nov 12; 34(46):5739-48.
Score: 0.003
-
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Res. 2015 Apr 15; 75(8):1635-44.
Score: 0.003
-
Immune checkpoint blockade and interferon-a in melanoma. Semin Oncol. 2015 Jun; 42(3):436-47.
Score: 0.003
-
Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. JAMA Dermatol. 2015 Feb; 151(2):212-8.
Score: 0.003
-
Classification of current anticancer immunotherapies. Oncotarget. 2014 Dec 30; 5(24):12472-508.
Score: 0.003
-
Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol. 2015 Jan; 16(1):15-7.
Score: 0.003
-
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar; 5(3):264-73.
Score: 0.003
-
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277.
Score: 0.003
-
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014 Nov 20; 32(33):3771-8.
Score: 0.003
-
Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy. Melanoma Res. 2014 Oct; 24(5):437-47.
Score: 0.003
-
Does metastasectomy improve survival in skeletal melanoma? Melanoma Res. 2014 Aug; 24(4):354-9.
Score: 0.003
-
Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res. 2014 Jun; 24(3):207-18.
Score: 0.003
-
PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41.
Score: 0.003
-
Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014 Jun 15; 20(12):3310-8.
Score: 0.003
-
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37.
Score: 0.003
-
Interferons in the therapy of solid tumors. Oncology. 1994 Mar-Apr; 51(2):129-36.
Score: 0.003
-
Systemic therapy of melanoma. Curr Opin Oncol. 1994 Mar; 6(2):204-11.
Score: 0.003
-
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.
Score: 0.003
-
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 Mar; 15(3):323-32.
Score: 0.003
-
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol. 2014 Mar; 15(3):297-304.
Score: 0.003
-
A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. PLoS One. 2014; 9(1):e86375.
Score: 0.003
-
The role of interferons in the therapy of melanoma. Immunol Ser. 1994; 61:239-50.
Score: 0.003
-
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8? T cells induced by melanoma vaccines. Cancer Res. 2014 Feb 15; 74(4):1045-55.
Score: 0.003
-
Melanoma brain metastases: an unmet challenge in the era of active therapy. Curr Oncol Rep. 2013 Oct; 15(5):483-91.
Score: 0.003
-
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98.
Score: 0.003
-
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One. 2013; 8(8):e69748.
Score: 0.003
-
Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8.
Score: 0.003
-
Pathologic and gene expression features of metastatic melanomas to the brain. Cancer. 2013 Aug 01; 119(15):2737-46.
Score: 0.003
-
Dysplastic nevi in relation to superficial spreading melanoma. Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr; 2(2):99-101.
Score: 0.003
-
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10; 31(5):616-22.
Score: 0.003
-
An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J Am Acad Dermatol. 1992 Nov; 27(5 Pt 1):741-9.
Score: 0.003
-
Characterization of an early passage Merkel cell polyomavirus-positive Merkel cell carcinoma cell line, MS-1, and its growth in NOD scid gamma mice. J Virol Methods. 2013 Jan; 187(1):6-14.
Score: 0.003
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov; 13(11):1087-95.
Score: 0.003
-
Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med. 2012 Sep 05; 10:185.
Score: 0.003
-
Mitochondrial respiration--an important therapeutic target in melanoma. PLoS One. 2012; 7(8):e40690.
Score: 0.003
-
A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One. 2012; 7(7):e40805.
Score: 0.003
-
The role of BRAF V600 mutation in melanoma. J Transl Med. 2012 Jul 09; 10:85.
Score: 0.003
-
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
Score: 0.003
-
Linear accelerator based stereotactic radiosurgery for melanoma brain metastases. J Cancer Res Ther. 2012 Apr-Jun; 8(2):215-21.
Score: 0.003
-
Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res. 1992 Feb 15; 52(4):851-6.
Score: 0.003
-
Interclinician agreement on the recognition of selected gross morphologic features of pigmented lesions. Studies of melanocytic nevi V. J Am Acad Dermatol. 1992 Feb; 26(2 Pt 1):185-90.
Score: 0.003
-
Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer. 2012 Aug 15; 131(4):874-84.
Score: 0.003
-
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res. 2012 Feb 15; 18(4):1129-37.
Score: 0.003
-
Mastectomy versus breast conservation surgery: mental health effects at long-term follow-up. Health Psychol. 1992; 11(6):349-54.
Score: 0.003
-
Comparison of nonfamilial and familial melanoma. Dermatology. 1992; 184(1):2-7.
Score: 0.003
-
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012 Feb 15; 72(4):887-96.
Score: 0.003
-
Effects of interferon-gamma and tumour necrosis factor-alpha on the development of cytotoxic T lymphocytes in autologous mixed lymphocyte tumour cultures with human melanoma. Clin Exp Immunol. 1991 Oct; 86(1):163-72.
Score: 0.003
-
Interferon alpha in combination with other biologics: the scientific rationale. Br J Haematol. 1991 Oct; 79 Suppl 1:78-80.
Score: 0.003
-
Studies of interferons in the therapy of melanoma. Semin Oncol. 1991 Oct; 18(5 Suppl 7):83-90.
Score: 0.003
-
Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI. Br J Cancer. 1991 Aug; 64(2):373-6.
Score: 0.003
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30; 364(26):2507-16.
Score: 0.003
-
Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. J Transl Med. 2011 May 26; 9:78.
Score: 0.003
-
Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med. 2011 May 05; 9:52.
Score: 0.003
-
A relation between childhood sun exposure and dysplastic nevus syndrome among patients with nonfamilial melanoma. Epidemiology. 1991 May; 2(3):210-4.
Score: 0.003
-
Granulocytopenia in cancer patients treated in a phase I trial with recombinant human tumor necrosis factor. J Immunother (1991). 1991 Apr; 10(2):84-95.
Score: 0.003
-
Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother. 2011 Apr; 34(3):270-8.
Score: 0.003
-
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011 Mar 26; 9:32.
Score: 0.003
-
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011; 16(1):5-24.
Score: 0.003
-
Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1. J Immunol. 2011 Jan 01; 186(1):312-22.
Score: 0.002
-
Role of interferons in the therapy of melanoma. J Invest Dermatol. 1990 Dec; 95(6 Suppl):180S-184S.
Score: 0.002
-
A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 1990 Oct; 8(10):1637-49.
Score: 0.002
-
Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer. 2010 Sep 15; 116(18):4326-33.
Score: 0.002
-
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010 Sep 27; 207(10):2175-86.
Score: 0.002
-
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med. 2010 Aug 16; 8:76.
Score: 0.002
-
Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct; 23(5):e1-7.
Score: 0.002
-
Interferon alpha-2a and dacarbazine in melanoma. J Natl Cancer Inst. 1990 Jun 20; 82(12):1062-3.
Score: 0.002
-
Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg. 2011 Mar; 114(3):769-79.
Score: 0.002
-
In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. J Clin Oncol. 1990 Jun; 8(6):1070-82.
Score: 0.002
-
Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J Immunol. 2010 Jun 15; 184(12):6709-18.
Score: 0.002
-
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.
Score: 0.002
-
Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med. 2010 Mar 19; 8:27.
Score: 0.002
-
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15; 116(6):1526-34.
Score: 0.002
-
Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosom Med. 1990 Jan-Feb; 52(1):73-85.
Score: 0.002
-
Fluorouracil, interferon-alpha, and colon cancer: rational pursuit of synergism between antimetabolites and biologicals. J Clin Oncol. 1989 Dec; 7(12):1764-5.
Score: 0.002
-
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20; 27(36):6199-206.
Score: 0.002
-
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009 Nov 15; 15(22):7036-44.
Score: 0.002
-
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011 Feb; 29(1):161-6.
Score: 0.002
-
Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer. 2009 Sep 15; 125(6):1243-9.
Score: 0.002
-
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res. 2009 Sep 15; 69(18):7459-65.
Score: 0.002
-
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med. 2009 Jul 29; 7:68.
Score: 0.002
-
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment Cell Melanoma Res. 2009 Oct; 22(5):532-43.
Score: 0.002
-
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med. 2009 Jun 17; 7:45.
Score: 0.002
-
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009 May 01; 182(9):5240-9.
Score: 0.002
-
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10; 27(17):2823-30.
Score: 0.002
-
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81.
Score: 0.002
-
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med. 2008 Dec 23; 6:81.
Score: 0.002
-
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10; 26(35):5748-54.
Score: 0.002
-
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer. 2008 Oct 01; 113(7):1632-40.
Score: 0.002
-
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother. 2008 Oct; 31(8):781-91.
Score: 0.002
-
A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 2008 Jun 01; 14(11):3462-9.
Score: 0.002
-
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol. 2008 May 10; 26(14):2292-8.
Score: 0.002
-
Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol. 2008 May; 127(2):123-9.
Score: 0.002
-
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 01; 26(13):2178-85.
Score: 0.002
-
Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med. 1988 May; 17(3):273-9.
Score: 0.002
-
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008 Mar 01; 112(5):982-94.
Score: 0.002
-
Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer. 2008 Mar 01; 112(5):1131-8.
Score: 0.002
-
Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol. 2008 Mar 01; 180(5):2967-80.
Score: 0.002
-
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008 Feb 20; 26(6):955-62.
Score: 0.002
-
Dysplastic nevi in association with multiple primary melanoma. Cancer Res. 1988 Feb 15; 48(4):1016-8.
Score: 0.002
-
Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients. J Immunol. 2007 Dec 01; 179(11):7932-40.
Score: 0.002
-
A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6796-806.
Score: 0.002
-
A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol. 1987 Nov; 5(11):1804-10.
Score: 0.002
-
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007 Sep 01; 25(25):3802-7.
Score: 0.002
-
Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018). J Clin Oncol. 1987 Aug; 5(8):1247-55.
Score: 0.002
-
Coumarin plus cimetidine: yet another angle for therapy of renal cell carcinoma. J Clin Oncol. 1987 Jun; 5(6):836-7.
Score: 0.002
-
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007 Apr 15; 13(8):2422-8.
Score: 0.002
-
Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007 Mar; 60(3):471-81; discussion 481-2.
Score: 0.002
-
SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene. 2007 Jun 21; 26(29):4216-25.
Score: 0.002
-
Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007 Feb 01; 109(3):455-64.
Score: 0.002
-
Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother. 2007 Jan; 30(1):75-82.
Score: 0.002
-
Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg. 2007; 54:241-7.
Score: 0.002
-
Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features. Ann Surg Oncol. 2006 Dec; 13(12):1664-70.
Score: 0.002
-
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006 Oct 10; 24(29):4738-45.
Score: 0.002
-
Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol. 1986 Sep; 13(3 Suppl 2):48-56.
Score: 0.002
-
Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15; 177(4):2717-27.
Score: 0.002
-
Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress. Mol Cancer Res. 2006 Aug; 4(8):575-89.
Score: 0.002
-
Prognostic role of antibody reactivity to melanoma. J Clin Invest. 1986 Apr; 77(4):1116-21.
Score: 0.002
-
Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. Melanoma Res. 2006 Apr; 16(2):165-74.
Score: 0.002
-
Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2291s-2296s.
Score: 0.002
-
Diagnosis of the dysplastic nevus in different populations. J Am Acad Dermatol. 1986 Mar; 14(3):419-25.
Score: 0.002
-
Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer. 2005 Dec 15; 104(12):2784-91.
Score: 0.002
-
Melanoma: therapeutic options with recombinant interferons. Semin Oncol. 1985 Dec; 12(4 Suppl 5):7-12.
Score: 0.002
-
Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005 Dec; 123(12):1639-43.
Score: 0.002
-
Update: current management issues in malignant melanoma. Melanoma Res. 2005 Oct; 15(5):319-24.
Score: 0.002
-
Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med. 1985 Jul; 103(1):32-6.
Score: 0.002
-
Antigenic phenotype of pigment cell lesions: a study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma. J Invest Dermatol. 1985 May; 84(5):430-2.
Score: 0.002
-
Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma: COMS Report No. 25. Arch Ophthalmol. 2005 May; 123(5):601-4.
Score: 0.002
-
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 01; 174(3):1751-9.
Score: 0.002
-
A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 1985 Feb; 45(2):863-71.
Score: 0.002
-
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005 Jan 01; 23(1):133-41.
Score: 0.002
-
Vitiligo and melanoma: can genetically abnormal melanocytes result in both vitiligo and melanoma within a single family? J Am Acad Dermatol. 1984 Oct; 11(4 Pt 1):696-701.
Score: 0.002
-
Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol. 2004 Jun 15; 22(12):2438-44.
Score: 0.002
-
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004 Jun 01; 22(11):2101-7.
Score: 0.002
-
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004 May-Jun; 54(3):131-49; quiz 182-4.
Score: 0.002
-
Interferons in the treatment of human cancer. J Clin Oncol. 1984 Apr; 2(4):336-52.
Score: 0.002
-
Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med. 1984 Apr; 76(4):593-6.
Score: 0.002
-
Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol. 1984 Mar; 2(3):164-8.
Score: 0.002
-
Regional isolated perfusion of high risk melanoma of the extremities with imidazole carboxamide. Surg Gynecol Obstet. 1984 Mar; 158(3):238-42.
Score: 0.002
-
Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes. Cancer Biol Ther. 2004 Jan; 3(1):110-20.
Score: 0.002
-
Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004 Mar; 50(3):564-73.
Score: 0.002
-
Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol. 2004 Jan 01; 22(1):11-4.
Score: 0.002
-
Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res. 2003 Dec; 13(6):619-26.
Score: 0.002
-
The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res. 2003 Oct 01; 63(19):6506-15.
Score: 0.002
-
In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome. Cancer Res. 1983 Jul; 43(7):3434-40.
Score: 0.001
-
Tomographic gallium-67 citrate scanning. Useful new surveillance for metastatic melanoma. Ann Surg. 1983 Jul; 198(1):102-7.
Score: 0.001
-
Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003 Jul 01; 98(1):100-9.
Score: 0.001
-
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res. 2003 Mar; 9(3):947-54.
Score: 0.001
-
Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials. J Biol Response Mod. 1983; 2(6):528-39.
Score: 0.001
-
Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials. J Biol Response Mod. 1983; 2(6):540-7.
Score: 0.001
-
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003; 21(1):43-52.
Score: 0.001
-
Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment. Mol Imaging. 2003 Jan; 2(1):65-73.
Score: 0.001
-
Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER). Cancer. 1982 Oct 01; 50(7):1299-303.
Score: 0.001
-
Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial. Cancer Chemother Pharmacol. 2002 Dec; 50(6):433-44.
Score: 0.001
-
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med. 2002 Sep 02; 196(5):619-28.
Score: 0.001
-
Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002 Mar 01; 20(5):1311-8.
Score: 0.001
-
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002 Mar-Apr; 25(2):97-138.
Score: 0.001
-
Phase II trial of mitolactol in patients with metastatic melanoma. Cancer Treat Rep. 1982 Jan; 66(1):195-6.
Score: 0.001
-
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33.
Score: 0.001
-
Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001 Dec; 8(10):766-70.
Score: 0.001
-
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001 Aug 15; 19(16):3622-34.
Score: 0.001
-
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001 Aug 15; 19(16):3635-48.
Score: 0.001
-
Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen. Cancer. 1981 May 15; 47(10):2414-21.
Score: 0.001
-
Burden of illness associated with metastatic melanoma: an audit of 100 consecutive referral center cases. Cancer. 2001 May 01; 91(9):1814-21.
Score: 0.001
-
Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol. 2001 Feb 01; 19(3):812-23.
Score: 0.001
-
Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs. 2001; 19(1):89-92.
Score: 0.001
-
Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther. 2000 Dec; 6(4):171-6.
Score: 0.001
-
Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res. 2000 Aug; 9(3):352-63.
Score: 0.001
-
Cytokine-based therapy for melanoma: pre-clinical studies. Forum (Genova). 2000 Jul-Sep; 10(3):204-26.
Score: 0.001
-
Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest. 2000 May; 29(2):121-5.
Score: 0.001
-
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000 Mar 15; 88(6):1484-91.
Score: 0.001
-
Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385). Med Oncol. 2000 Feb; 17(1):47-51.
Score: 0.001
-
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A. 2000 Jan 04; 97(1):400-5.
Score: 0.001
-
Melanoma: a multidisciplinary overview of current concepts and management. Conn Med. 1980 Jan; 44(1):21-6.
Score: 0.001
-
Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma. Mol Med. 1999 Dec; 5(12):785-94.
Score: 0.001
-
A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep; 25(3):199-206.
Score: 0.001
-
Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther. 1999 May 20; 10(8):1261-8.
Score: 0.001
-
Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):581-9.
Score: 0.001
-
Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys. 1998 Sep 01; 42(2):269-76.
Score: 0.001
-
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998 May; 16(5):1743-51.
Score: 0.001
-
Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol. 1997 Nov; 15(11):3399-407.
Score: 0.001
-
A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1997 Jun; 20(3):251-3.
Score: 0.001
-
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol. 1997 Jun; 15(6):2351-8.
Score: 0.001
-
Recent advances in the care of the patient with malignant melanoma. Ann Surg. 1997 Jan; 225(1):1-14.
Score: 0.001
-
Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Am J Clin Oncol. 1996 Dec; 19(6):546-51.
Score: 0.001
-
Molecular analysis of melanoma precursor lesions. Cell Growth Differ. 1996 Dec; 7(12):1733-40.
Score: 0.001
-
Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol. 1996 Nov; 19(6):433-42.
Score: 0.001
-
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996 Oct; 14(10):2666-73.
Score: 0.001
-
Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections. Cytometry. 1996 Sep 01; 25(1):71-81.
Score: 0.001
-
Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res. 1996 Aug; 2(8):1263-74.
Score: 0.001
-
Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res. 1996 Jan; 2(1):29-36.
Score: 0.001
-
Isolation of a new foamy retrovirus from orangutans. J Virol. 1994 Nov; 68(11):7124-30.
Score: 0.001
-
Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol. 1994 Feb; 15(2):134-9.
Score: 0.001
-
Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1993 Apr; 13(3):201-7.
Score: 0.001
-
Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 1991 Dec 15; 51(24):6691-4.
Score: 0.001
-
Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1991 Oct; 9(10):1806-10.
Score: 0.001
-
High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst. 1990 Dec 19; 82(24):1934-7.
Score: 0.001
-
Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model. Nat Immun Cell Growth Regul. 1990; 9(5):313-24.
Score: 0.001
-
Isolation and partial characterization of melanoma-associated antigens identified by autologous antibody. J Clin Invest. 1988 Jun; 81(6):1746-51.
Score: 0.001
-
Human melanocytes cultured from nevi and melanomas. J Invest Dermatol. 1986 Jul; 87(1):95-101.
Score: 0.000
-
Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res. 1985 Apr; 45(4):1855-61.
Score: 0.000
-
Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat Rep. 1984 May; 68(5):723-6.
Score: 0.000
-
Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev. 1984 Mar; 11(1):1-26.
Score: 0.000
-
Effect of intravenous recombinant alpha-2 interferon on monocyte Fc-dependent phagocytosis in patients with malignant melanoma. J Interferon Res. 1984; 4(2):215-21.
Score: 0.000
-
Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983 Nov; 9(5):689-96.
Score: 0.000
-
Uveal findings in patients with cutaneous melanoma. Am J Ophthalmol. 1983 Apr; 95(4):474-9.
Score: 0.000
-
Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities. Surgery. 1982 Sep; 92(3):459-63.
Score: 0.000
-
High-dose fraction radiation therapy for intracranial metastases of malignant melanoma: a comparison with low-dose fraction therapy. Cancer. 1982 Jun 01; 49(11):2289-94.
Score: 0.000